Le Lézard
Classified in: Health
Subject: TDS

FDAnews Announces -- Early Bird Pricing Ends on May 3, EU-Medical Device Regulation and In-vitro Diagnostic Compliance Workshop June 10-12, 2019 Waltham, MA

FALLS CHURCH, Va., April 26, 2019 /PRNewswire-PRWeb/ -- EU-Medical Device Regulation and In-vitro Diagnostic Compliance Workshop
Interactive Workshop Training from FDAnews and Ombu Enterprises
June 10-12, 2019 ? Waltham, MA (Boston)

Early bird pricing for EU-Medical Device Regulation and In-vitro Diagnostic Compliance Workshop ends on May 3.

Understanding and Implementing the EU-MDR & EU-IVDR: June 10-11, 2019
Post-Market Activities in the EU-MDR ? A Detailed Analysis: June 12, 2019

The EU-MDR and IVDR compliance clocks are ticking... daily. Many devicemakers still aren't ready to meet the Dates of Application. The new regulations are very complicated sets of rules!

And that's just for openers.

The new regulations are a handful. They will change the way one does business in the European Union!

Here's how we can help...

Mark the calendar for two, or three, productive days of hands-on training with Dan O'Leary of Ombu Enterprises, one of FDAnews' most in-demand trainers. Over the course of two days (June 10-11), attendees will understand the conversion and implement the new MDR:

Special Third-Day Add-On:
Post-Market Activities in the EU-MDR ? A Detailed Analysis

Stay one more day. Participate in a workshop untangling one of the most complicated aspects of the new EU-MDR post-market activities ? one will discover:

This add-on workshop assumes a basic familiarity with the EU-MDR. Attending the previous day's workshop (June 10-11) is recommended but not required to attend this (June 12) day.

The first EU-MDR compliance deadline falls in May 2020, less than a year after this workshop. There's no time to waste and space is limited. Reserve a seat today.

Early bird pricing ends on Friday May 3.

Who Should Attend:

Webinar Details:
Building a World-Class Advertising and Promotion Review Program
**A Two-Day Interactive Workshop Presented by PhillyCooke Consulting and FDAnews**
May 7-8, 2019 Boston, MA

Early Bird Pricing Course I (Days 1&2): $1,597 (available until May 3, 2019)
Regular Pricing Course I (Days 1&2): $1,797 (after May 3, 2019)
Early Bird Pricing Course II (Day 3): $797 (available until May 3, 2019)
Regular Pricing Course II (Day 3): $897 (after May 3, 2019)
Early Bird Pricing Course I & II: $1,947 (available until May 3, 2019)
Regular Pricing Course I & II: $2,197 (available until May 3, 2019)
Significant team discounts are available.

Easy Ways to Register:
Online: https://www.fdanews.com/eumdreg
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.



These press releases may also interest you

at 04:35
The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a new report by Grand View Research, Inc. Allogenic tissue transplant method efficiently addresses challenges and...

at 04:23
Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The...

at 04:00
As governments in many countries are easing lockdown restrictions, fitness facilities are getting ready to re-open and welcome back customers. After the pandemic, health has certainly risen to the top of the list of consumers' personal priorities,...

at 03:30
The "Global Molecular Point of Care (mPOC) Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The molecular point of care (mPOC) devices market is poised to grow by $ 816.62 million during 2020-2024 progressing at...

at 03:25
Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the ongoing EMA review of imlifidase for a potential marketing authorization in Europe is on track. A CHMP opinion is expected at...

at 02:05
POXEL S.A. (Euronext ? POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) ("Poxel", or the "Company"),...

News published on 26 april 2019 at 00:00 and distributed by: